Anika Therapeutics Inc. Cost of Revenue

Cost of Revenue of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending September 29, 2021 was $16.5 Million (a -4.73% decrease compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 3.58%
  • Annual Cost of Revenue for 2020 was $61.4 Million (a 113.7% increase from previous year)
  • Annual Cost of Revenue for 2019 was $28.7 Million (a -8.1% decrease from previous year)
  • Annual Cost of Revenue for 2018 was $31.3 Million (a 14.31% increase from previous year)
  • Twelve month Cost of Revenue ending September 29, 2021 was $63.1 Million (a 3.55% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 2.73% year-over-year
Trailing Cost of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$63.1 Million $60.9 Million $60.5 Million $61.4 Million
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Anika Therapeutics Inc.

Most recent Cost of Revenueof ANIK including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Anika Therapeutics Inc.

Anika Therapeutics Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $16.51 $17.33 $13.32
2020 $15.94 $14.35 $16.94 $14.2 $61.43
2019 $8.65 $5.95 $6.84 $7.31 $28.75
2018 $7.0 $8.28 $8.15 $7.85 $31.28
2017 $8.72 $6.25 $6.32 $6.08 $27.36
2016 $7.54 $5.0 $6.07 $5.43 $24.03
2015 $6.29 $5.18 $5.28 $4.31 $21.05
2014 $5.51 $5.72 $5.33 $4.36 $20.93
2013 $6.23 $5.38 $6.31 $4.84 $22.77
2012 $7.27 $7.22 $8.08 $6.41 $28.99
2011 $7.13 $7.39 $6.66 $5.6 $26.78
2010 $6.7 $23.83

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.